Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate) in the phase 3 DEFINE and CONFIRM trials

被引：0
|
作者：
Selmaj, K. [1 ]
Gold, R. [2 ]
Fox, R. J. [3 ]
Havrdova, E. [4 ]
Giovannoni, G. [5 ]
Pace, A.
Novas, M.
Meltzer, L.
Hotermans, C.
Viglietta, V.
Phillips, J. T. [6 ]
机构：
[1] Med Univ Lodz, Lodz, Poland
[2] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[4] Charles Univ Prague, Prague, Czech Republic
[5] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[6] Baylor Inst Immunol Res, Dallas, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：221 / 221
页数：1
相关论文
共 50 条
  • [31] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study
    Hutchinson, Michael
    Fox, Robert J.
    Miller, David H.
    Phillips, J. Theodore
    Kita, Mariko
    Havrdova, Eva
    O'Gorman, John
    Zhang, Ray
    Novas, Mark
    Viglietta, Vissia
    Dawson, Katherine T.
    JOURNAL OF NEUROLOGY, 2013, 260 (09) : 2286 - 2296
  • [32] Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study
    Fox, Robert
    Miller, David
    Phillips, J. Theodore
    Kita, Mariko
    Hutchinson, Michael
    Havrdova, Eva
    Yang, Minhua
    Zhang, Ray
    Viglietta, Vissia
    Dawson, Katherine
    NEUROLOGY, 2012, 78
  • [33] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study
    Bar-Or, Amit
    Gold, Ralf
    Kappos, Ludwig
    Arnold, Douglas L.
    Giovannoni, Gavin
    Selmaj, Krzysztof
    O'Gorman, John
    Stephan, Monica
    Dawson, Katherine T.
    JOURNAL OF NEUROLOGY, 2013, 260 (09) : 2297 - 2305
  • [34] Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
    Hutchinson, M.
    Fox, R. J.
    Miller, D.
    Phillips, J. T.
    Kita, M.
    Havrdova, E.
    Yang, M.
    Zhang, R.
    Novas, M.
    Viglietta, V.
    Dawson, K. T.
    JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S106
  • [35] Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis) study
    Hutchinson, M.
    Fox, R. J.
    Miller, D.
    Phillips, J. T.
    Kita, M.
    Havrdova, E.
    O'Gorman, J.
    Yang, M.
    Novas, M.
    Viglietta, V.
    Dawson, K. T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 355 - 355
  • [36] Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis
    Kappos, Ludwig
    Giovannoni, Gavin
    Gold, Ralf
    Fox, Robert
    Phillips, J. Theodore
    Hotermans, Christophe
    Zhang, Annie
    Viglietta, Vissia
    Miller, David
    NEUROLOGY, 2013, 80
  • [37] Clinical efficacy of BG-12 in relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Gold, R.
    Miller, D. H.
    Phillips, J. T.
    Arnold, D. L.
    Selmaj, K.
    Yang, M.
    Zhang, R.
    Dawson, K. T.
    Viglietta, V.
    Sheikh, S. I.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 48 - 49
  • [38] Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study
    Kita, M.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Sarda, S. P.
    Kong, J.
    Zhang, R.
    Viglietta, V.
    Sheikh, S. I.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 530 - 530
  • [39] Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies
    Gold, R.
    Phillips, J. T.
    Bar-Or, A.
    Hutchinson, M.
    Kappos, L.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 222 - 222
  • [40] Clinical effects of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Kita, M.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    Hutchinson, M.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 191 - 191
12345